Mfsd2a is critical for the formation and function of the blood-brain barrier.
Level 5 - mechanism / opinion, no new human data
Bench and animal model research with no human data
PubMed 24828040 · doi:10.1038/nature13324
What was done
Researchers tracked blood-brain barrier (BBB) functional timing in mouse embryos using a tracer-injection method, performed gene expression screening during BBB development, and evaluated the role of *Mfsd2a* using knockout mice (*Mfsd2a*−/−). BBB permeability, vascular patterning, and endothelial ultrastructure were examined via tracer assays and electron microscopy across embryonic and adult stages.
What was found
The mouse BBB became functional at embryonic day 15.5 (E15.5). *Mfsd2a* was selectively expressed in CNS blood vessels and was regulated by pericytes. Genetic deletion of *Mfsd2a* caused persistent BBB leakage from embryonic development through adulthood despite normal vascular patterning. Electron microscopy demonstrated increased endothelial vesicular transcytosis without apparent tight-junction abnormalities. Specific quantitative effect sizes or counts were not reported in the abstract.
Why it matters
This study identifies Mfsd2a as a critical molecular regulator of BBB integrity that functions primarily by suppressing transcytosis rather than altering tight junctions, highlighting a potential target for modulating CNS drug delivery.
Limits
The study was conducted entirely in mice, so findings may not fully translate to human BBB biology. The abstract does not provide sample sizes, quantitative effect sizes, or statistical confidence intervals.
Cited by
- supports Hotspots of MFSD2A transporter reduction on cerebral blood vessels colocalize with areas of pericyte loss.